Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 26, 2023
April 8, 2024
f58b2adc-b92a-4458-b269-5346d25a8a39
Related Documents
Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry
Guidance DocumentAugust 29, 2019Center for Drug Evaluation and Research
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment: Guidance for Industry; Availability
Guidance DocumentOctober 17, 2022Office of the Commissioner
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry
Guidance DocumentJuly 27, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.